Breaking Finance News

A statement released earlier today by Needham & Company LLC about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) drops the target price to $137.00

Having a price of $70.30, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded -5.36% lower on the day. With the last close up -48.12% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. ALNY has recorded a 50-day moving average of $70.69 and a 200-day moving average of $66.05. 5,197,185 shares of the stock were exchanged, up from an average trading volume of 981,972

In a statement issued on Thursday October 06, 2016 Needham & Company LLC bumped down the target of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from $152.00 to $137.00 reporting a potential upside of 0.95%.

On 9/29/2016, Janney Capital released a statement about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) upped the target price from $0.00 to $74.00 that suggested a downside of -0.03%.

See Chart Below

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. has a 52 week low of $33.16 and a 52 week high of $110.75 ALNY’s total market value is presently $0.

A total of 11 equity analysts have released a research note on ALNY. Three equity analysts rating the company a strong buy, eight equity analysts rating the company a buy, two equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $117.09.

Brief Synopsis About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.